Table 6.

HRs for Disease-Free and Overall Survival for One-Unit Increases in lnCRP and lnSAA, Stratified by Joint ER/PR Status (localized and regional stage disease only)

Survival	ER Positive/PR Positive				ER Negative/PR Negative				ER Negative/PR Positive				ER Positive/PR Negative
	No. of Events	No. of Participants	HR	95% CI	No. of Events	No. of Participants	HR	95% CI	No. of Events	No. of Participants	HR	95% CI	No. of Events	No. of Participants	HR	95% CI
Overall survival
lnCRP	41	302	1.39	1.05 to 1.86	14	88	2.01	0.96 to 4.02	2	16	—*	—*	7	62	—*	—*
lnSAA	41	302	1.89	1.30 to 2.74	14	88	2.84	1.03 to 7.86	2	16	—*	—*	7	62	—*	—*
Disease-free survival
lnCRP	36	299	0.98	0.69 to 1.39	14	87	1.49	0.71 to 3.13	2	16	—*	—*	9	61	—*	—*
lnSAA	36	299	1.36	0.83 to 2.15	14	87	2.09	0.81 to 5.39	2	16	—*	—*	9	61	—*	—*

NOTE. HRs were adjusted for age (continuous), disease stage, race/study site, body mass index (continuous), and comorbidities (histories of heart failure and myocardial infarction.

Abbreviations: HR, hazard ratio; ER, estrogen receptor; PR, progesterone receptor.

^*There were too few events for regression to converge.